Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
Holding SNDX?
Track your performance easily
SNDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.22 - $25.34
Previous Close$18.2
Volume1.11M
Average Volume (3M)1.05M
Market Cap
$1.55B
Enterprise Value$1.12B
Total Cash (Recent Filing)$425.10M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 06, 2024EPS Estimate
-$1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding85,096,358
10 Day Avg. Volume1,208,970
30 Day Avg. Volume1,051,997
Standard Deviation0.16
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.57
Price to Sales (P/S)464.87
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue321.36
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.27
Forecast
1Y Price Target
$34.56Price Target Upside91.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Syndax Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe FDA approved Niktimvo (axatilimab) for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.
Market ExpansionSyndax and partner Incyte are seeking a label adjustment to include two new vial sizes which may provide additional commercial benefits.
Revenue PotentialSyndax is eligible to receive up to $220M in future development and regulatory milestones and up to $230M in commercialization milestones.
Bears Say
Competitive LandscapeUncertainties regarding revumenib and rival Kura’s ziftomenib seen as advantaged over the longer-term.
Market PositioningLaunch delay puts pressure on first mover advantage.
Regulatory IssuesSentiment taking a hit following FDA’s recent 3 mos PDUFA extension to menin inhibitor revumenib.
---
Ownership Overview
1.05% Insiders
21.72% Mutual Funds
61.58% Other Institutional Investors
15.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $11.21 and its highest was $25.34 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Aug 01, 2024. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$0.911 by $0.111.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -$1.13.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 85,096,360 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.8 in its last earnings report, beating expectations of -$0.911. Following the earnings report the stock price went down -4.364%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Among the largest hedge funds holding Syndax Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Syndax Pharmaceuticals Inc’s shares valued at 32M.
---
Syndax Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.56 (91.36% Upside)
$34.56 (91.36% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 983.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.83%
12-Months-Change
Fundamentals
Return on Equity
-63.30%
Trailing 12-Months
Asset Growth
10.57%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
---
SNDX Company Deck
---
SNDX Earnings Call
Q2 2024
0:00 / 0:00
---
SNDX Stock 12 Month Forecast
Average Price Target
$34.56
▲(91.36% Upside)
Technical Analysis
Best Analysts Covering SNDX
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+37.08%
reiterated a buy rating last month
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +37.08% per trade.
---